問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans Center Hospital Yuli Branch (在職)

Division of Hematology & Oncology

Division of Psychiatry

China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Yuli Hospital Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of Psychiatry

National Taiwan University Hospital Yunlin Branch  (在職)

Division of Psychiatry

國立臺灣大學醫學院附設醫院雲林分院

更新時間：2023-09-19

陳姿婷Chen, Tzu-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

91Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳姿婷

List

156Cases

2019-12-01 - 2025-12-31

Phase III

Active
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia

  • Condition/Disease

    Untreated Chronic Lymphocytic Leukemia

  • Test Drug

    Acalabrutinib (ACP-196)

Participate Sites
9Sites

Recruiting4Sites

Terminated5Sites

2021-04-01 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2024-02-01 - 2038-01-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    EpcoritamabLenalidomideObinutuzumab RituximabCyclophosphamideDoxorubicinVincristineVincristinePrednisoneBendamustine

Participate Sites
4Sites

Recruiting4Sites

2019-02-01 - 2022-12-31

Phase I/II

A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

  • Condition/Disease

    Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

  • Test Drug

    Glofitamab、Obinutuzumab、Tocilizumab

Participate Sites
2Sites

Recruiting2Sites

2020-10-01 - 2025-12-31

Phase I

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia

  • Condition/Disease

    Relapsed/Refractory Acute Myeloid Leukemia

  • Test Drug

    RO7283420

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2018-12-28 - 2022-12-31

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma

  • Condition/Disease

    Classical Hodgkin lymphoma (CHL), diffuse large B-cell lymphoma(DLBCL) or Peripheral T-Cell Lymphoma

  • Test Drug

    Isatuximab

Participate Sites
4Sites

Recruiting3Sites

2017-12-01 - 2025-12-31

Phase III

A Phase 3 randomized, open-label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant

  • Condition/Disease

    Newly Diagnosed Multiple Myeloma (NDMM)

  • Test Drug

    Isatuximab

Participate Sites
5Sites

Recruiting4Sites

2017-03-01 - 2019-09-30

Phase II

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Condition/Disease

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Test Drug

    SP-02L

Participate Sites
6Sites

Terminated5Sites

2007-12-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-03-01 - 2009-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 7 8 9 10 11 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB